Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27837899 | 0.90 | GSK3B (0.81) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL29011091 | 0.88 | RAB9A (0.88) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL27855638 | 0.88 | RAB9A (1.00) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL27837901 | 0.88 | GSK3B (0.78) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL28615859 | 0.88 | GSK3B (0.78) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL28622100 | 0.88 | GSK3B (0.78) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL30386353 | 0.88 | GSK3B (0.78) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL17377349 | 0.88 | GSK3B (0.78) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL17377357 | 0.84 | GSK3B (0.86) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL28629744 | 0.84 | GSK3B (0.71) | GSK3BRAB9ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073235-A1 | IN VITRO EXPANSION OF DOPAMINERGIC SUBTYPE NEURONAL PROGENITORS DERIVED FROM PLURIPOTENT STEM CELLS | Wisconsin Alumni Research Foundation (US) | 2022-10-19 | — | — | EP | claimed |
| CN-115151633-A | In vitro expansion of pluripotent stem cell-derived dopaminergic subtype neuronal progenitor cells | 威斯康星校友研究基金会 | 2022-10-04 | — | — | CN | claimed |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2022-06-16 | — | — | US | claimed |
| EP-3907279-A1 | NOVEL GLIA-LIKE CELLS DIFFERENTIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2021-11-10 | — | — | EP | claimed |
| US-20190032018-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2019-01-31 | — | — | US | claimed |
| WO-2018160028-A1 | MEDIUM COMPOSITION FOR NEURON DIFFERENTIATION AND METHOD FOR DIFFERENTIATING SOMATIC CELLS INTO NEURONS USING SAME MEDIUM COMPOSITION | 주식회사 셀라토즈테라퓨틱스 | 2018-09-07 | — | — | WO | claimed |
| WO-2018155913-A1 | METHOD FOR DIFFERENTIATION INTO SKELETAL MUSCLE CELL USING LOW-MOLECULAR WEIGHT COMPOUND | 성균관대학교산학협력단 | 2018-08-30 | — | — | WO | claimed |
| US-20160251624-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2016-09-01 | — | — | US | claimed |
| EP-3060649-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-08-31 | — | — | EP | claimed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | claimed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| WO-2015061568-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| WO-2012034101-A2 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | claimed |
| WO-2025106671-A1 | PERSONALIZED PROGENITOR CELLS | IMMORTA BIO, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12104169-B2 | Chemical reprogramming to generate neuronal cells | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2024-10-01 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | GMFG, HGF, BDNF | GSK3B 293/4885RAB9A 3482/4885NPC1 1420/4885 |
| US-20160251624-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | POU2F1, POU5F1, POU2F2 | GSK3B 1412/4885RAB9A 3375/4885NPC1 4503/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | GSK3B 795/4885RAB9A 1294/4885NPC1 4035/4885 |
| US-20190032018-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | POU2F1, POU5F1, POU2F2 | GSK3B 1412/4885RAB9A 3375/4885NPC1 4503/4885 |
| US-12104169-B2 | Chemical reprogramming to generate neuronal cells | CHAT, DCX, NES | GSK3B 846/4885RAB9A 1481/4885NPC1 2242/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | GSK3B 2586/4885RAB9A 4578/4885NPC1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.